Research dossier
Clinical research on Chromium
6 trials reviewed across 5 indications.
Strongest evidence
Blood sugar control
Mechanism
Chromium proposed to enhance insulin receptor signaling via low-molecular-weight chromium binding protein (LMWCr). The mechanism is well described biochemically — whether it translates to clinical glucose control in well-fed adults is the question that has repeatedly failed in trials.
The Anderson 1997 Chinese trial put chromium on the blood-sugar map. Western replication has been disappointing: Kleefstra 2006 and the Yin 2015 meta-analysis of 14 RCTs both found no significant HbA1c effect from chromium picolinate. The clean read: in trace-mineral-adequate populations, chromium does not meaningfully improve glycemic control.
Possible benefit in genuinely chromium-deficient populations. No reliable benefit in Western adults at typical chromium intake.
Trials cited
Anderson — chromium picolinate in type 2 diabetes
positive · RCT
Anderson et al., 1997, DiabetesOften-cited Chinese trial that reported improvements in fasting glucose, HbA1c, and insulin at 1000 mcg/day chromium picolinate over 4 months in adults with type 2 diabetes. The trial put chromium on the supplement map for blood-sugar marketing — but it has not replicated cleanly in subsequent Western trials.
The study population had higher chromium deficiency than typical Western adults. Subsequent attempts to reproduce the effect in iodine-replete and trace-mineral-adequate Western populations have largely failed.
Kleefstra — chromium in poorly controlled type 2 diabetes (Western population)
Null · RCT
Kleefstra et al., 2006, Diabetes CareRandomized trial in a Western population with insulin-treated type 2 diabetes found no effect of chromium on glycemic control. Directly contradicts the Anderson 1997 result and supports the broader pattern: chromium does not work in trace-mineral-adequate populations.
One of the cleaner negative trials in chromium's blood-sugar story. The picolinate marketing largely ignores it.
Chromium supplementation meta-analysis in type 2 diabetes
Null · Meta-analysis
Yin & Phung 2015, Diabetes Research and Clinical Practicen=875Pooled across 14 trials and 875 patients, chromium picolinate and chromium yeast showed no statistically significant effect on HbA1c. Only brewer's yeast (which contains chromium plus other compounds) produced a small fasting glucose reduction. The clean read: chromium picolinate, the most heavily marketed form, fails the meta-analytic test for HbA1c.
The brewer's yeast signal cannot be attributed to chromium specifically — the matrix contains B vitamins, amino acids, and other factors.
Cofactor function
Mechanism
Trivalent chromium (Cr3+) is the biologically active form. The proposed mechanism involves enhancement of insulin signaling via low-molecular-weight chromium binding protein (LMWCr). Frank deficiency produces glucose intolerance — but documented human deficiency is essentially limited to long-term parenteral nutrition cases.
Chromium is conditionally essential at trace levels. Adequate intake is met by virtually any diet — broccoli, whole grains, meat, and brewer's yeast all contribute. Routine supplementation in healthy adults solves a problem most people don't have.
Adequacy through diet is the rule. Isolated supplementation has no clear clinical indication for healthy adults.
Energy and weight loss claims
Mechanism
Marketing claims propose chromium enhances energy metabolism and reduces appetite. The mechanism is speculative.
There is no controlled-trial evidence that chromium supplementation produces meaningful weight loss or energy improvement. Modest signals in some short-term trials have not replicated. The aggressive marketing of chromium picolinate for weight loss is not supported by quality evidence.
No clinical evidence for weight-loss benefit. Marketing claims considerably outrun the data.
Chromium supplementation meta-analysis in type 2 diabetes
Null · Meta-analysis
Yin & Phung 2015, Diabetes Research and Clinical Practicen=875Pooled across 14 trials and 875 patients, chromium picolinate and chromium yeast showed no statistically significant effect on HbA1c. Only brewer's yeast (which contains chromium plus other compounds) produced a small fasting glucose reduction. The clean read: chromium picolinate, the most heavily marketed form, fails the meta-analytic test for HbA1c.
The brewer's yeast signal cannot be attributed to chromium specifically — the matrix contains B vitamins, amino acids, and other factors.
Cardiometabolic outcomes
Mechanism
Marketing positions chromium as a cardiometabolic supplement via its proposed glucose effects. The blood pressure mechanism is not established.
The Ghanbari 2022 meta-analysis of 11 RCTs found no effect of chromium on systolic or diastolic blood pressure. Combined with the negative HbA1c findings, chromium has no demonstrated cardiometabolic benefit at standard supplement doses.
No controlled-trial support for cardiometabolic supplementation with chromium.
Chromium and blood pressure — systematic review and meta-analysis
Null · Meta-analysis
Ghanbari et al., 2022, European Journal of Clinical NutritionSystematic review of 11 randomized trials found no significant overall effect of chromium supplementation on systolic or diastolic blood pressure. Closes off another marketing claim for chromium products positioning themselves on cardiometabolic outcomes.
Confirms that chromium's blood-pressure marketing has no controlled-trial backing.
Cognition (preliminary)
Mechanism
Krikorian's trial showed fMRI activation changes in semantic memory regions. Mechanism for the cognition signal is not well characterized.
One small (n=26) trial in older adults showed reduced semantic interference and increased brain activation on fMRI, but no improvement in learning or retention. Sample size is too small for firm conclusions and the trial has not been replicated.
Preliminary signal only. Not a basis for chromium supplementation for cognition.
Chromium picolinate and cognition in older adults at risk for neurodegeneration
mixed · RCT
Krikorian et al., 2010, Nutritional Neurosciencen=26Small (n=26) trial showed reduced semantic interference on memory tasks and increased fMRI activation in cognition-relevant brain regions. Learning and retention themselves were not enhanced. The signal is preliminary and underpowered.
Sample size too small to draw firm conclusions. Has not been replicated.
5 forms of Chromium compared
Chromax
Chromium picolinate
Better absorbed than inorganic forms
Best forMost-studied and most-marketed formPicolinic acid carrier. Most clinical trials used this form — most of those trials were null. In vitro toxicology suggests chronic high-dose picolinate can cause cellular DNA damage; the clinical relevance is unclear, but it argues against chronic high-dose use.
Chromium polynicotinate
Adequate
Best forNiacin-bound chromium; alternative to picolinateBound to niacin. Less studied than picolinate. No clear clinical advantage.
Chromium chloride
Lower than chelated forms
Best forOlder inorganic formInorganic salt. Largely supplanted by picolinate and yeast forms.
Chromium-enriched brewer's yeast
Good — chromium presented as a natural complex
Best forThe form that showed the only meaningful glucose signal in the Yin 2015 meta-analysisNote that the meta-analysis benefit cannot be cleanly attributed to chromium itself — yeast contains B vitamins, amino acids, and other compounds that may drive the effect.
Chromium GTF (glucose tolerance factor)
Variable
Best forMarketing term for chromium-yeast complexesGTF was a hypothesized natural chromium complex. Modern biochemistry is skeptical the original GTF molecule exists as proposed. Often a marketing label for chromium-yeast products.
Are you deficient? Symptoms, risk groups, lab tests
Documented chromium deficiency in humans is essentially limited to long-term parenteral nutrition cases without chromium. Frank dietary deficiency is not a recognized clinical entity in adults eating any normal diet.
Common symptoms
- Insulin resistance and impaired glucose tolerance (in documented severe deficiency)
- Unexplained weight loss
- Confusion or impaired cognition
- Peripheral neuropathy (in severe parenteral nutrition cases)
Who is at risk
Patients on long-term parenteral nutrition without chromium
Bypasses dietary intake; the only realistic clinical setting for chromium deficiency.
Side effects and drug interactions
Side effects
GI upset (nausea, stomach irritation, diarrhea)
Common · Above 1000 mcg/day
Most common side effect, particularly above 1000 mcg/day.
Hypoglycemia in adults on diabetes medication
Uncommon
Chromium's modest glucose-lowering effect can stack with metformin, sulfonylureas, or insulin and cause low blood sugar.
Cellular DNA damage (in vitro signal at chronic high doses)
Uncommon · Chronic intake well above 1000 mcg/day
In vitro and rodent toxicology data raise concern about chronic high-dose chromium picolinate. The clinical relevance is unclear, but it is the form most likely to be problematic at sustained high intake.
Worse with:chromium picolinate
Gentler:chromium-enriched yeast (if supplementation is desired at all)
Mild headaches, dizziness, mood disturbance
Uncommon
Reported uncommonly with chromium supplementation.
Allergic reactions (rash, itching)
Rare
Rare hypersensitivity reactions reported.
Drug interactions
Combined-effect risk
metforminsulfonylureas (glipizide, glyburide)insulinChromium's modest glucose-lowering effects can stack with diabetes medication and cause hypoglycemia.
If you are on diabetes medication and want to try chromium, monitor blood glucose closely and discuss with your prescriber.
Additive effect
NSAIDs (aspirin, ibuprofen)NSAIDs may increase chromium absorption.
Monitor chromium intake if combining with chronic NSAID use.
Reduces nutrient status
antacidsH2 blockersproton pump inhibitorsReduce chromium absorption.
Separate dosing by 2 hours.
Reduces nutrient status
levothyroxinePossible interference with thyroid hormone absorption.
Separate dosing by 3-4 hours from levothyroxine.
Other critical caveats
- Marketing claims for chromium as a blood-sugar or weight-loss supplement run well ahead of the evidence. The Yin 2015 meta-analysis of 14 trials found no HbA1c effect from chromium picolinate.
- Adults on diabetes medication should not start chromium without monitoring — the modest glucose-lowering effect can compound with metformin or insulin and cause hypoglycemia.
- Chromium picolinate is the most heavily marketed and most aggressively dosed form. In vitro toxicology suggests chronic high-dose picolinate can cause cellular DNA damage. Clinical relevance is unclear, but it argues against chronic mega-dosing.
- Hexavalent chromium (Cr6+) is industrial pollution and carcinogenic. Trivalent chromium (Cr3+) in supplements is a different chemical species — but this is no excuse for blanket reassurance about chronic supplementation.
Frequently asked
Does chromium help with blood sugar?
The marketing says yes; the controlled trials say mostly no. The most-cited Anderson 1997 trial in China found benefit at 1000 mcg/day, but Western replication trials (Kleefstra 2006) and the 2015 meta-analysis of 14 RCTs found no HbA1c effect from chromium picolinate. In trace-mineral-adequate populations — most Western adults — chromium does not meaningfully control blood sugar.Will chromium help me lose weight?
No. The weight-loss marketing for chromium picolinate is not supported by quality controlled trials. Modest short-term signals have not replicated in larger or longer studies. Save your money.Is chromium picolinate safe?
At typical multivitamin doses (35-200 mcg/day), the safety profile is acceptable. The concern is with chronic mega-dosing — in vitro and rodent toxicology data suggest chromium picolinate at high doses can cause cellular DNA damage. The clinical relevance for human supplement users is unclear, but it argues against chronic intake well above 1000 mcg/day.Can I take chromium with metformin?
Don't combine without monitoring. Chromium's modest glucose-lowering effect can stack with metformin, sulfonylureas, or insulin and cause hypoglycemia. If you want to try chromium and you are on diabetes medication, talk to your prescriber and check your blood glucose more often than usual.What about chromium for cravings?
There is a small literature on chromium and atypical depression with carbohydrate cravings, but the trials are few, small, and not consistently replicated. This is not an evidence-based use case in the way it is sometimes marketed.
References
- 01NIH Office of Dietary Supplements — Chromium Health Professional Fact Sheet
- 02Yin & Phung — Chromium meta-analysis in T2DM (Diab Res Clin Pract, 2015)
- 03Anderson — Chromium picolinate in T2DM (Diabetes, 1997)
Last reviewed2026-05-07